Manipal Group Sets Up Stem Cell Arm in Malaysia (Malaysia)
This article was originally published in PharmAsia News
Executive Summary
Stempeutics Research Pvt. Lab recently disclosed plans to open a subsidiary in Malaysia. The startup will be dubbed Stempeutics Research Malaysia Sdn Bhd. Stempeutic's parent company, the India-based Manipal Education and Medical, will invest between $6 million and $10 million in Stempeutics Malaysia over the next three years. Manipal will also use Stempeutics Malaysia as a jumping off point for research and commercialization in Taiwan and Singapore. Manipal has already invested $7 million in Stempeutics for the company's stem cell research program. Stempeutics is currently researching the prospect of using adult stem cells to treat a number of ailments, including myocardial infarction, multiple sclerosis, limb ischemia and cerebral stroke. Adult stem cells come in two forms. The first are autologous stem cells that are harvested from the patient's own bone marrow. Stempeutics is already conducting several clinical trials into the possible benefits of these stem cells. The company is also waiting for approval from the Indian Council of Medical Research to conduct trials with allogenic stem cells. This type of adult stem cell comes from non-related donor cells. Allogenic stem cells have the benefit of being produced on a large scale. Manipal plans to invest $5 million over the next two years to build a cell manufacturing plant in India. (Click here for more
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.